Details for Patent: 9,849,122
✉ Email this page to a colleague
Title: | Combination therapy |
Abstract: | Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt. |
Inventor(s): | Kopczynski; Casey (Chapel Hill, NC), Lin; Cheng-Wen (Raleigh, NC), Sturdivant; Jill Marie (Chapel Hill, NC), deLong; Mitchell A. (Chapel Hill, NC) |
Assignee: | Aerie Pharmaceuticals, Inc. (Durham, NC) |
Filing Date: | Apr 29, 2016 |
Application Number: | 15/142,461 |
Claims: | 1. A compound according to formula (II): ##STR00041## or a pharmaceutically acceptable salt thereof, wherein: Y is phenylene; B is --NR.sub.1R.sub.2 or --CH.sub.2NR.sub.1R.sub.2; R.sub.1 and R.sub.2 are each independently hydrogen or C.sub.1-C.sub.4 alkyl; X.sub.1 and X.sub.2 are hydrogen; and PG is an acyl radical of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, unoprostone, or PGF.sub.2.alpha.. 2. The compound of claim 1, wherein: B is --CH.sub.2NR.sub.1R.sub.2; and R.sub.1 and R.sub.2 are hydrogen. 3. The compound of claim 1, wherein PG is an acyl radical of latanoprost. 4. The compound of claim 1, wherein PG is an acyl radical of AR-102. 5. The compound of claim 1, wherein PG is an acyl radical of bimatoprost. 6. A composition comprising a compound of claim 1, and at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar or a sugar alcohol, or a surfactant. 7. The compound of claim 1, wherein PG is an acyl radical of travoprost. 8. A method of treating glaucoma in a subject in need thereof, comprising administering to the subject a compound of claim 1. 9. The method of claim 8, wherein the compound is administered topically to an eye of the subject. 10. A method of reducing intraocular pressure in a subject in need thereof, comprising topically administering to an eye of the subject a compound of claim 1. 11. A compound, wherein the compound is: ##STR00042## or a pharmaceutically acceptable salt thereof. 12. A composition comprising a compound of claim 11, further comprising at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar or a sugar alcohol, or a surfactant. 13. A method of treating glaucoma in a subject in need thereof, comprising administering to the subject a compound of claim 11. 14. The method of claim 13, wherein the compound is administered topically to an eye of the subject. 15. A method of reducing intraocular pressure in a subject in need thereof, comprising topically administering to an eye of the subject a compound of claim 11. 16. A compound according to formula (II): ##STR00043## or a pharmaceutically acceptable salt thereof; wherein Y is phenylene; B is --CH.sub.2NR.sub.1R.sub.2; R.sub.1 and R.sub.2 are hydrogen; X.sub.1 and X.sub.2 are hydrogen; and PG is an acyl radical of latanoprost. 17. A composition comprising a compound of claim 16, further comprising at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar or a sugar alcohol, or a surfactant. 18. A method of treating glaucoma in a subject in need thereof, comprising administering to the subject a compound of claim 16. 19. The method of claim 18, wherein the compound is administered topically to an eye of the subject. 20. A method of reducing intraocular pressure in a subject in need thereof, comprising topically administering to an eye of the subject a compound of claim 16. 21. The compound of claim 2, wherein PG is an acyl radical of bimatoprost. |